Published in Med Dosim on June 06, 2009
Treatment techniques to reduce cardiac irradiation for breast cancer patients treated with breast-conserving surgery and radiation therapy: a review. Front Oncol (2014) 0.88
Radiation pneumonitis in breast cancer patients who received radiotherapy using the partially wide tangent technique after breast conserving surgery. J Breast Cancer (2012) 0.84
Radiation Pneumonitis in Association with Internal Mammary Node Irradiation in Breast Cancer Patients: An Ancillary Result from the KROG 08-06 Study. J Breast Cancer (2016) 0.75
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2009) 2.29
Therapeutic advances in non-small cell lung cancer. Thorax (2011) 2.21
Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? Lancet Oncol (2009) 2.13
Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys (2007) 2.02
Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev (2005) 1.85
Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys (2004) 1.78
Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol (2007) 1.47
Thymoma: a focus on current therapeutic management. J Thorac Oncol (2009) 1.29
Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett (2012) 1.24
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics (2004) 1.21
Brain stem metastases treated with radiosurgery: prognostic factors of survival and life expectancy estimation. Surg Neurol (2008) 1.20
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol (2002) 1.19
MRI-based low dose-rate brachytherapy experience in locally advanced cervical cancer patients initially treated by concomitant chemoradiotherapy. Radiother Oncol (2010) 1.18
Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys (2008) 1.17
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys (2006) 1.13
Is radiologic placement of an arm port mandatory in oncology patients?: analysis of a large bi-institutional experience. Cancer (2007) 1.11
Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol (2010) 1.08
Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev (2014) 1.01
Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol (2005) 1.00
Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol (2010) 1.00
DVH parameters and outcome for patients with early-stage cervical cancer treated with preoperative MRI-based low dose rate brachytherapy followed by surgery. Radiother Oncol (2009) 0.96
Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med (2004) 0.95
Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. Breast Cancer Res Treat (2012) 0.93
Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol (2015) 0.93
Extraskeletal Osteosarcoma: An International Rare Cancer Network Study. Am J Clin Oncol (2016) 0.93
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol (2011) 0.93
Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys (2006) 0.92
Inverse planning approach for 3-D MRI-based pulse-dose rate intracavitary brachytherapy in cervix cancer. Int J Radiat Oncol Biol Phys (2007) 0.89
Evaluation of the radiobiological impact of anatomic modifications during radiation therapy for head and neck cancer: can we simply summate the dose? Radiother Oncol (2010) 0.89
Impact of glycosylation on the effect of cytokines. A special focus on oncology. Eur Cytokine Netw (2002) 0.88
Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit? Cancer Treat Rev (2008) 0.87
Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev (2010) 0.84
Cannon ball lucencies from last century: lucite balls used to treat pulmonary tuberculosis. Indian J Chest Dis Allied Sci (2010) 0.84
Recommendations for a lifestyle which could prevent breast cancer and its relapse: physical activity and dietetic aspects. Crit Rev Oncol Hematol (2011) 0.83
Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. Int J Radiat Oncol Biol Phys (2005) 0.83
Curative-intended treatment of squamous cell anal carcinoma in elderly adults. J Am Geriatr Soc (2012) 0.83
Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients. Am J Clin Oncol (2012) 0.82
The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg (2002) 0.82
Carcinoma in situ at the bronchial resection margin: a review. J Thorac Oncol (2011) 0.81
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. Eur J Cancer (2008) 0.80
First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma: data on safety and efficacy. Anticancer Drugs (2013) 0.80
IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer. Anticancer Res (2012) 0.79
OSNA (one-step nucleic acid amplification) sentinel lymph node intraoperative molecular analysis in breast cancer: a cost-benefit analysis. Med Oncol (2014) 0.79
Adjuvant chemotherapy and radiotherapy in non-small cell lung cancer. Semin Radiat Oncol (2004) 0.79
Concomitant chemo-radiotherapy as standard therapy in limited-stage small-cell oesophageal cancer: a summary of 3 clinical cases and review of the literature. Acta Gastroenterol Belg (2009) 0.79
[Cancer stem cells, cornerstone of radioresistance and perspectives for radiosensitization: glioblastoma as an example]. Bull Cancer (2012) 0.78
[The announcement of the diagnosis of cancer: point of view of the general practitioner]. Bull Cancer (2013) 0.78
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients. Chemotherapy (2016) 0.78
Prostate needle biopsy examination by means of virtual microscopy. Pathol Res Pract (2011) 0.78
[Cisplatin or carboplatin, that is the question]. Bull Cancer (2011) 0.78
Is it possible to improve radiotherapy team members' communication skills? A randomized study assessing the efficacy of a 38-h communication skills training program. Radiother Oncol (2013) 0.78
Metabolic functional imaging for tumor radiosensitivity monitoring. Crit Rev Oncol Hematol (2007) 0.78
Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol (2009) 0.78
Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53. Int J Radiat Oncol Biol Phys (2007) 0.77
Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Clin Genitourin Cancer (2012) 0.77
[Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast]. Bull Cancer (2003) 0.77
Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia. Biomed J (2015) 0.76
Impact on cardiac toxicity with trastuzumab and radiotherapy: the question is still ongoing. J Clin Oncol (2009) 0.76
[Assessment of daily physical activity of breast cancer patients and comparison with two control populations]. Bull Cancer (2011) 0.76
Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report. Anticancer Drugs (2016) 0.76
Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience. Chemotherapy (2016) 0.76
Features of cancer management in obese patients. Crit Rev Oncol Hematol (2012) 0.75
Computed tomography-based simulation for thoracic radiation therapy: technical advance or clinical evidence? J Clin Oncol (2011) 0.75
Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use. J Chemother (2013) 0.75
Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis. Cell Stress Chaperones (2013) 0.75
Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma. World J Radiol (2013) 0.75
[Axillary lymph node irradiation in breast cancer: state of the art]. Bull Cancer (2012) 0.75
Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored? Int Urol Nephrol (2015) 0.75
Reapprasial of the role of endocrine therapy in meningioma management. Endocr Relat Cancer (2008) 0.75
[Pharmacological consequences of the targeting of epidermal growth factor receptor]. Bull Cancer (2003) 0.75
Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clin Exp Metastasis (2006) 0.75
Correlation of dosimetric parameters obtained with the analytical anisotropic algorithm and toxicity of chest chemoradiation in lung carcinoma. Med Dosim (2011) 0.75
Preventing radiotherapy-induced side effects on deep brain stimulators: the need for a multidisciplinary management. Br J Neurosurg (2013) 0.75
Radiotherapy for head and neck cancer in nonagenarian patients: a possible cornerstone? Eur Arch Otorhinolaryngol (2014) 0.75
[Establishment of a pilot study of awareness retraining in physical activity in two selected populations of patients with breast cancer]. Bull Cancer (2012) 0.75
The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. Cancer Chemother Pharmacol (2002) 0.75
A federal audit of the Belgian radiotherapy departments in breast cancer treatment. Radiother Oncol (2007) 0.75
[Guidelines of clinical practice made by the European Lung Cancer Working Party: updates]. Rev Med Brux (2014) 0.75
Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer (2004) 0.75
Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Radiother Oncol (2008) 0.75
Medical physics principles of radiosurgery. Prog Neurol Surg (2007) 0.75
[Carcinoma of the anal canal: state of art, issues in geriatric oncology and molecular targeted therapies]. Bull Cancer (2011) 0.75
Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents. Cancer Metastasis Rev (2008) 0.75
[Brachial fluoroscopically guided implantation of venous port devices in oncology patients]. Bull Cancer (2002) 0.75
[Chemoradiation therapy: a model for treatment optimization in oncology]. Bull Cancer (2006) 0.75
Safety of spinal radiotherapy in metastatic cancer patients receiving bevacizumab therapy: a bi-institutional case series. Anticancer Drugs (2015) 0.75
[Metastasis of a lumbosacral ependymoma with very long disease-free survival: a case report and review of the literature]. Cancer Radiother (2006) 0.75
[Targeted therapies and radiotherapy in colorectal cancer]. Bull Cancer (2005) 0.75